Marea Drug Cuts Triglycerides Up to 72%
A Phase 2b trial of MAR001, an ANGPTL4-targeting antibody, showed sustained triglyceride reductions in adults.
Updated on Nov. 9, 2026 in Diabetes

Marea Therapeutics reported that its investigational antibody MAR001 met the primary endpoint at all three tested doses in Part A of the Phase 2b TYDAL-TIMI 78 trial, reducing fasting triglycerides by up to 72.2% in patients with the highest baseline levels. The results were presented at the American Heart Association Scientific Sessions 2026 and published in the New England Journal of Medicine.
Why it matters
Elevated triglycerides are a persistent cardiovascular risk that many patients do not fully control with existing therapies, so a drug that lowers them substantially and durably could address an unmet need. The trial's results also support advancing Marea's program toward later-stage development.
The Phase 2b trial enrolled 235 adults in Part A, with placebo-adjusted triglyceride reductions of 39.1% to 45.5% at 12 weeks versus placebo, and 51.7% of highest-dose patients reached triglycerides below 150 mg/dL compared with 3.4% on placebo. Whether these reductions translate into reduced cardiovascular events has not yet been tested in this study.
The players
Marea Therapeutics
Marea Therapeutics is the biotechnology company developing MAR001 and its planned longer-acting successor MAR005.
American Heart Association
The American Heart Association is a major U.S. nonprofit focused on cardiovascular disease research and public health, which hosted the Scientific Sessions where the results were presented.
The details
MAR001 is a monoclonal antibody that targets ANGPTL4, given every four weeks for 24 weeks in Part A, with reductions in fasting triglycerides sustained through Week 24. Treatment-emergent adverse events occurred in 69.5% of MAR001 recipients versus 77.6% on placebo, serious adverse events in 2.8% versus 6.9%, and no pancreatitis cases or deaths were reported.
Timeline
Week 12: primary endpoint for triglyceride reduction measured.
Week 24: triglyceride reductions confirmed as sustained.
November 9, 2026: results announced at AHA Scientific Sessions 2026 and published in NEJM.
Health Landscape
The results extend a line of research into ANGPTL-targeting drugs, which lower triglycerides by acting on a different pathway than statins and fibrates. Triglyceride-lowering therapies remain a less crowded area of cardiovascular drug development than LDL cholesterol treatment.
If later trials confirm these results, patients with persistently high triglycerides could gain a new injectable option beyond current oral medications. The trial's side-effect profile, with fewer serious adverse events than placebo, is an early signal but not yet a guarantee of safety in broader use.
The takeaway
Triglyceride levels are a modifiable cardiovascular risk factor, and new drug classes targeting them are an active area of research. Patients concerned about triglycerides should discuss their levels and options with a clinician.
What happens next
Marea is enrolling Part B of the TYDAL-TIMI 78 trial and developing MAR005 as its planned Phase 3 candidate.
Further reading
Explore more on Diabetes to see how triglyceride control fits into metabolic health care.







